Trastuzumab deruxtecan (Enhertu) significantly improved PFS compared with standard of care as a first-line treatment for HER2-mutant nonsquamous NSCLC. Topline results were announced from the phase 3 ...
In a special episode of the MPR Weekly Dose podcast, Dr William Schaffner — professor of preventive medicine and infectious diseases at Vanderbilt University School of Medicine and former CDC Epidemic ...
The phase 3 ALKIVIA study met its primary endpoint, demonstrating significant and sustained improvements in disease activity and muscle strength for patients with active autoimmune myositis.
States are moving faster and further than federal regulators to get kratom off store shelves, with some banning the herb outright while a pending federal rule targets only one of its chemicals.
The device enables eligible adult wheelchair users living with spinal cord injury to walk and perform some activities of daily living.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results